<DOC>
	<DOCNO>NCT00251472</DOCNO>
	<brief_summary>This Phase II , open-label , non-randomized study patient locally advance metastatic breast cancer . Each cycle treatment 4 week length . Patients radiologically evaluate every 8 week response . Patients continue receive study treatment disease progression unacceptable toxicity .</brief_summary>
	<brief_title>A Phase II Trial Abraxane™ Given Weekly Single Agent First-line Treatment Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>To eligible study , patient must fulfill follow criterion : Patients must sign IRBapproved informed consent . Patients must histologically pathologically confirm document locally advanced metastatic breast cancer . Patients may Her2+ Her2 . Patients must measurable disease , define lesion accurately measure least one dimension &gt; 2 cm conventional technique &gt; 1 cm spiral CT scan . Palpable disease acceptable . Patients must &gt; 18 year age . Patients must ECOG Performance Status 0 1 ( see Appendix I ) . Patients ' estimate life expectancy must least 12 week . Patients may receive prior adjuvant chemotherapy breast cancer , include taxanecontaining regimen , provide treatment complete least 12 month prior enrollment . Patients may receive prior radiation ( except radiation entire pelvis ) , provide less 25 % bone marrow treat , patient recover acute toxic effect treatment prior trial enrollment . Prior radiation treatment must complete least 4 week prior enrollment . Lesions irradiate advanced disease setting may include site measurable disease . Patients may receive prior hormonal , AI ( aromatase inhibitor ) therapy , immunotherapy . All hormonal , AI , immunotherapy must terminate prior enrollment . Patients must adequate liver function define : patient liver metastasis , aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , bilirubin level 1.5 time upper limit normal ( ULN ) . For patient liver metastasis , ALT , AST , bilirubin level 2.5 time ULN . Patients must adequate renal function define : creatinine &lt; 2mg/dL calculated creatinine clearance must &gt; 40mL/min . Patients must adequate bone marrow function , include absolute neutrophil count ( ANC ) ³1500/µL , platelet count ³100,000/µL , hemoglobin ³9 g/dL . Patients must either child bear potential negative serum pregnancy test within 7 day prior registration . Patients consider child bear potential surgically sterile ( undergone hysterectomy , bilateral tubal ligation bilateral oophorectomy ) postmenopausal least 12 month . Patients childbearing potential must agree use effective contraceptive measure study treatment reasonable time thereafter . Patients must willing able comply schedule visit , treatment plan laboratory testing , accessible followup . Any following criterion make patient ineligible participate study : Patients receive prior chemotherapy treatment metastatic breast cancer . Patients receive prior Abraxane . Patients history hypersensitivity taxanes component taxanes Abraxane . Patients serious intercurrent medical psychiatric illness . Patients second primary malignancy , except carcinoma situ cervix adequately treat nonmelanomatous carcinoma skin malignancy treat &gt; 5 year previously evidence recurrence . Patients nonmeasurable disease , define lesion include small lesion truly nonmeasurable lesion . Patients parenchymal leptomeningeal brain metastasis . Patients plan receive concurrent therapy treat metastatic locally advanced breast cancer study treatment period . Any patient pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>